Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

Khashayar Esfahani, Tho-Alfakar Al-Aubodah, Paméla Thébault, Réjean Lapointe, Marie Hudson, Nathalie A. Johnson, Dana Baran, Najwa Bhulaiga, Tomoko Takano, Jean‐François Cailhier,

Nature Communications · 2019 · 105 citations · 26 references

DOIFull text

Open access

Concepts

Abstract

Abstract Immune checkpoint inhibitor (ICI) use remains a challenge in patients with solid organ allografts as most would undergo rejection. In a melanoma patient in whom programmed-death 1 (PD-1) blockade resulted in organ rejection and colitis, the addition of the mTOR inhibitor sirolimus resulted in ongoing anti-tumor efficacy while promoting allograft tolerance. Strong granzyme B + , interferon (IFN)-γ + CD8 + cytotoxic T cell and circulating regulatory T (T reg ) cell responses were noted during allograft rejection, along with significant eosinophilia and elevated serum IL-5 and eotaxin levels. Co-treatment with sirolimus abated cytotoxic T cell numbers and eosinophilia, while elevated T reg cell numbers in the peripheral blood were maintained. Interestingly, numbers of IFN-γ + CD4 + T cells and serum IFN-γ levels increased with the addition of sirolimus treatment likely promoting ongoing anti-PD-1 efficacy. Thus, our results indicate that sirolimus has the potential to uncouple anti-PD-1 therapy toxicity and efficacy.

References

26